Two Mountains Psy-Tech
Effective Stop-Smoking Program at Scale, as for-profit Social Impact. 7 million – 8 million deaths/year from smoking (WHO). Mosquitoes only kill 1 million people/year. 70% of Western smokers make 1-2 attempts/year to quit smoking. Smoking cessation success rates are less than casino odds! 3-9% chance of quitting. 75% of smokers don’t seek help; 3-6% chance of quitting. 23% seek help, usually nicotine patches or gum, but more often now smokers are buying vapes; 8-9% smoking cessation success. 2% take prescription medication! 14% success. Nicotine patches and gum sell $4 billion/year. 100% purchased by smokers trying to quit. Vapes sell $32 billion/year. 85% purchased by smokers trying to quit. UK NHS ran 1 pilot project in Stevenage; Dr. Caitlin Notley lead researcher, and reported 42% smoking cessation! 12-month follow-up reported only 9% smoking cessation success. Recidivism back to smoking got most of them. Why? 40%+ smoking cessation success is possible. Quitting is only part of the problem. Recidivism back to smoking is the other part. Effective Stop-Smoking Program at Scale addresses both of these problems. But the experiment must be run to prove it!
Competitive advantage / usp – What is the one thing your product/service does better than anything else?
There are 5 major improvements or more in this Effective Stop-Smoking Program. We combine an improved, patented ‘smoking cessation’ vape with optimized, long-duration program delivery specifically engineered to significantly reduce recidivism back to smoking. Please see our Pitch Deck and Social Impact Plan for deeper details.
What is the problem you are trying to solve, and how do you know it’s actually a problem?
Smoking causes 7 million to 8 million deaths annually worldwide according to the WHO, yet current smoking cessation success rates are less than casino odds at 3-9%. While 70% of Western smokers make 1-2 attempts to quit each year, 75% do not seek professional help. Existing methods yield low success: vapes/patches achieve 8-9% success, and prescription medication sits at 14%. Data shows a massive market with nicotine patches/gum capturing $4 billion/year and vapes capturing $32 billion/year—all driven by smokers trying to quit. Furthermore, structural case studies like the UK NHS Stevenage pilot proved that while a 42% short-term cessation rate is possible, 12-month follow-ups reveal a drop to 9% success due to unaddressed recidivism. Quitting is only half the battle; stopping long-term relapse is the problem we are solving.
Demographics – Who is your target customer?
Our target customer base consists strictly of entrenched, pack-a-day smokers within internationally active Western markets who are actively attempting or motivated to break their severe nicotine addiction.
Revenue model – How do you actually make/plan to make money?
We monetize through a Direct-to-Consumer (D2C) 1-year subscription framework. This comprehensive structure ensures continuous, long-duration program engagement to systematically safeguard users against relapse. Detailed projections can be found inside our Social Impact Plan.
How big is the total addressable market, and what percentage do you realistically aim to capture in 5 years?
The core addressable market spans 100 million active smokers divided equally between North America (50 million) and Europe (50 million). Statistically, 70% of this population makes 1-2 automated quit attempts annually, isolating a pool of 70 million high-intent prospects. Within this ecosystem, 20% represent entrenched pack-a-day smokers, yielding an immediate target segment of 14 million individuals evenly split as 7 million EU/UK smokers and 7 million North American smokers. Our strategic low-hanging fruit phase will deliberately focus on capturing market share within this high-density segment of entrenched daily smokers.